Sign In
Buy BIOA
$22.32
+0.85 (+3.96%)
At Close: Jun 23, 2026
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular ris
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
04:58pm, Monday, 08'th Jun 2026
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
08:05am, Saturday, 06'th Jun 2026
BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company's plans for BGE-102, its lead NLRP3 inhibitor, with near-term readout
BioAge Labs to Present at Upcoming Investor Conferences
09:00am, Friday, 22'nd May 2026
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for me
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher inf
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
04:02pm, Friday, 08'th May 2026
BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across ca
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
09:00am, Friday, 08'th May 2026
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
04:30pm, Monday, 04'th May 2026
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disea
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
03:12am, Sunday, 26'th Apr 2026
BioAge Labs (NASDAQ: BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory bio
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
06:41pm, Friday, 24'th Apr 2026
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
11:07am, Tuesday, 21'st Apr 2026
BioAge Labs Inc (NASDAQ:BIOA) shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 inhibitor.
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
10:57am, Tuesday, 21'st Apr 2026
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dos
BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year
04:20pm, Wednesday, 15'th Apr 2026
BioAge Labs is rated Buy, leveraging strong early data for BGE-102, a novel oral NLRP3 inhibitor targeting cardiovascular and ophthalmology markets. BGE-102 achieved 86% hsCRP reduction and favorable
